COMPASS THERAPEUTICS, INC.
80 Guest Street
Suite 601
Boston, Massachusetts 02135
January 13, 2023
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Compass Therapeutics, Inc.: Registration Statement on Form S-3 filed December 2, 2022 (File No. 333-268652) |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Compass Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to January 17, 2023, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact James Xu of Goodwin Procter LLP at (650) 752-3355.
| Sincerely, |
| Compass Therapeutics, Inc. |
| /s/ Vered Bisker-Leib |
| Vered Bisker-Leib |
| President and Chief Operating Officer |
| cc: Vered Bisker-Leib, Compass Therapeutics, Inc. |
| Jonathan Anderman, Compass Therapeutics, Inc. |
| Richard Hoffman, Esq., Goodwin Procter LLP |
| James Xu, Esq., Goodwin Procter LLP |